Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | GPR6 | P46095 | 6/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14715699 | 1.00 | GRM2 (0.47) | GRM2DRD2HRH1CCR3SLC6A4 | |
| SCHEMBL3086108 | 0.88 | DRD2 (0.46) | DRD2HRH1CCR3SLC6A4 | |
| SCHEMBL3086106 | 0.88 | DRD2 (0.46) | DRD2HRH1CCR3SLC6A4 | |
| SCHEMBL3087227 | 0.86 | DRD2 (0.39) | GRM2DRD2SLC6A4HRH3 | |
| SCHEMBL3963647 | 0.86 | DRD2 (0.39) | GRM2DRD2SLC6A4HRH3 | |
| SCHEMBL14715697 | 0.86 | HRH1 (0.46) | GRM2HRH1CCR3GPR6 | |
| SCHEMBL3963825 | 0.86 | HRH1 (0.46) | GRM2HRH1CCR3GPR6 | |
| SCHEMBL3087873 | 0.85 | HRH1 (0.41) | GRM2DRD2HRH1CCR3SLC6A4 | |
| SCHEMBL3079710 | 0.85 | HRH1 (0.41) | GRM2DRD2HRH1CCR3SLC6A4 | |
| SCHEMBL14715744 | 0.85 | HRH3 (0.44) | HRH1GPR6HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079693-B1 | ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2013-02-27 | — | — | EP | claimed |
| EP-2079693-B1 | ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2013-02-27 | — | — | EP | disclosed |
| US-7795437-B2 | Ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-14 | — | — | US | disclosed |
| EP-2079693-A1 | ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F. Hoffmann-Roche AG (CH) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008052899-A1 | ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-08 | — | — | WO | disclosed |
| US-20080103174-A1 | ETHER DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103174-A1 | ETHER DERIVATIVES | GABRE, BDNF, ADH1A | GRM2 69/4885DRD2 59/4885HRH1 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.